Investigational drug · Phase 3
Tigulixostat
Also called: IBI128, LC350189
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gout, Hyperuricemia, Gout Flare.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
5
Any phase or sponsor naming "Tigulixostat"
First trial start
2023
Mar 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tigulixostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gout
- Hyperuricemia
- Gout Flare
- Tophi
Approved drugs for the same conditions: Gout
Largest trials
Live from ClinicalTrials.gov: studies naming "Tigulixostat" as an intervention, largest first.
- Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout PatientsPivotal-lookingCompleted
LG ChemIndustry
NCT05586971 · 2,202 participants · Start Mar 30, 2023 · Primary completion May 6, 2025
Drug: Tigulixostat; Allopurinol and 1 more · For: Gout; Hyperuricemia; Gout Flare and 1 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 279 sites in all
- Tigulixostat (IBI128) vs Febuxostat in GoutPivotal-lookingActive, not recruiting
Innovent Biologics Technology Limited (Shanghai R&D Center)Industry
NCT07414394 · 600 participants · Start Mar 17, 2026 · Primary completion Apr 30, 2027
Drug: Febuxostat; Tigulixostat · For: Gout
Sites: Shanghai, China
- Tigulixostat, Phase 3 Study, Placebo Controlled in Gout PatientsPivotal-lookingCompleted
LG ChemIndustry
NCT05586958 · 354 participants · Start Oct 25, 2022 · Primary completion Nov 4, 2024
Drug: Tigulixostat; Placebo · For: Gout; Hyperuricemia; Gout Flare and 1 more
Sites: Birmingham, Alabama; Covina, California; Clearwater, Florida · 52 sites in all
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06501534 · 84 participants · Start Jul 10, 2024 · Primary completion Dec 13, 2024
Drug: Febuxostat; IBI128 · For: Gout; Hyperuricemia
Sites: Shanghai, China
LG ChemIndustry
NCT06189404 · 24 participants · Start Oct 31, 2023 · Primary completion Nov 13, 2023
Drug: Tigulixostat; Theophylline · For: Gout; Hyperuricemia
Sites: Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
- A Phase I Dose-Escalation Study of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Oral Dose of Tigulixostat.
Tao J, Liu S, Liu R, et al. · Drug Des Devel Ther 2025
- Gout therapy updated.
McCarty KL, Gaffo AL, Diaz-Torne C · Ther Adv Musculoskelet Dis 2025
- Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies.
Saag KG, Dalbeth N, Hsu CY, et al. · Contemp Clin Trials 2025
- Tigulixostat Alleviates Hyperuricemic Nephropathy by Promoting M2 Macrophage Polarization.
Xue L, Tao Q, Chang H, et al. · J Inflamm Res 2025
- Pipeline Therapies for Gout.
Yip K, Braverman G, Yue L, et al. · Curr Rheumatol Rep 2024
- Comment on serum urate-lowering efficacy and safety of Tigulixostat in gout patients with hyperuricemia: A randomized, double-blind, placebo-controlled, dose-finding trial.
Hsu TM, Chang HW, Chen AL, et al. · Int J Rheum Dis 2024
Also in development for Gout
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.